Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695448 · ClinicalTrials.gov registry record · Phase 1
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00695448 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 11 participants.
The verdict
NCT00695448, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2 dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.
Interventions
- DRUG GSK1059615
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-06-24 |
| Est. Completion | 2009-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00695448
The ClinicalTrials.gov registry entry for NCT00695448 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1059615 is the first listed.
NCT00695448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00695448 about?
NCT00695448 is a clinical study titled "Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma". This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2 dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.
What is the current status of trial NCT00695448?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2008-06-24. Estimated completion is 2009-03-31.
What interventions are being tested in trial NCT00695448?
The interventions under investigation include: GSK1059615 (DRUG).
Who is sponsoring clinical trial NCT00695448?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.